Related Experiment Video
Updated: May 17, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
Ferumoxytol in clinical practice: implications for MRI
Brendan J McCullough1, Orpheus Kolokythas, Jeffrey H Maki
1Department of Radiology, University of Washington, Seattle, Washington 98195, USA. brenmcc@uw.edu
Abstract:
Ferumoxytol is an iron-containing parenteral treatment for iron deficiency anemia that was recently approved by the Food and Drug Administration. The iron is in the form of a superparamagnetic iron oxide that causes T1, T2, and T2* shortening on magnetic resonance imaging (MRI). Furthermore, the drug has a long intravascular half-life of 14-15 hours; a standard dose can affect MRI for days to months. We describe a case in which a patient underwent contrast-enhanced MRI of the liver 2 days after receiving a dose of ferumoxytol, which was unknown to the radiology team. The blood pool and soft tissues were hyperintense on T1-weighted images, concealing enhancement from the gadolinium-based contrast agent that was administered during the exam and rendering the exam nondiagnostic. Radiologists must be aware of this potential effect in screening patients for MRI and interpreting exams.
Insights
Ferumoxytol, an iron deficiency anemia treatment, can significantly alter MRI scans for days or months due to its iron oxide composition. This can mask contrast enhancement, leading to nondiagnostic liver imaging.
Area of Science:
- Radiology
- Pharmacology
- Medical Imaging
Background:
- Ferumoxytol is an FDA-approved parenteral iron replacement therapy for iron deficiency anemia.
- The drug contains superparamagnetic iron oxide particles with a long intravascular half-life.
- These particles induce T1, T2, and T2* signal shortening in MRI.
Observation:
- A patient underwent liver MRI 2 days after receiving ferumoxytol.
- The radiology team was unaware of the ferumoxytol administration.
- T1-weighted images showed hyperintensity in blood pools and soft tissues.
Findings:
- Ferumoxytol administration resulted in obscured enhancement from gadolinium-based contrast agents.
- The observed signal changes rendered the contrast-enhanced liver MRI nondiagnostic.
- The effects of ferumoxytol on MRI can persist for days to months post-administration.
Implications:
- Radiologists must be aware of ferumoxytol's potential to interfere with MRI interpretation.
- Screening patients for recent ferumoxytol administration is crucial before MRI.
- Understanding ferumoxytol's impact on MRI is essential for accurate diagnosis.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies III: Computed Tomography

